Urokinase
From Proteopedia
| Line 1: | Line 1: | ||
{{STRUCTURE_1c5w| PDB=1c5w | SIZE=400| SCENE= |right|CAPTION=Human urokinase short chain (grey) and catalytic domain (green) complex with inhibitor and citrate, [[1c5w]] }} | {{STRUCTURE_1c5w| PDB=1c5w | SIZE=400| SCENE= |right|CAPTION=Human urokinase short chain (grey) and catalytic domain (green) complex with inhibitor and citrate, [[1c5w]] }} | ||
| - | '''Urokinase''' (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage. | + | '''Urokinase''' (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178). |
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
| Line 9: | Line 9: | ||
Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} | ||
| - | [[2i9a]] - hUK Hc N terminal | + | [[2i9a]] - hUK Hc N terminal (residues 21-163) - human<br /> |
| - | [[1kdu]] – hUK kringle domain | + | [[1kdu]] – hUK kringle domain (residues 69-153) - NMR<br /> |
| - | [[4dva]] – hUK catalytic domain<br /> | + | [[4dva]] – hUK catalytic domain (residues 179-431) <br /> |
| - | ===Urokinase | + | ===Urokinase catalytic domain complex with inhibitors=== |
| + | |||
| + | [[4fu7]], [[4fu8]], [[4fu9]], [[4fub]] - hUK + inhibitor<br /> | ||
| + | [[1fv9]] – hUK (mutant) + benzimidazole derivative – human<br /> | ||
| + | [[1f5k]] - hUK (mutant) + benzamidine derivative<br /> | ||
| + | [[1f5l]] - hUK (mutant) + amiloride derivative<br /> | ||
| + | [[1f92]], [[1sc8]], [[1vj9]], [[1vja]], [[2o8t]], [[2o8u]], [[2o8w]], [[4h42]] - hUK (mutant) + inhibitor<br /> | ||
| + | [[1owd]], [[1owe]], [[1owh]], [[1owi]], [[1owj]], [[1owk]], [[1sqa]], [[1sqo]], [[1u6q]], [[1sqt]], [[4fuc]], [[4fud]], [[4fue]], [[4fuf]], [[4fug]], [[4fuh]], [[4fui]], [[4fuj]]- hUK + naphthamidine inhibitor<br /> | ||
| + | [[1ejn]] - hUK (mutant) + urea derivative inhibitor<br /> | ||
| + | [[2vin]], [[2vio]], [[2vip]], [[2viq]], [[2viv]], [[2viw]] - hUK (mutant) + mexiletine derivative<br /> | ||
| + | [[3qn7]], [[4jk5]], [[4jk6]] - hUK (mutant) + peptide inhibitor<br /> | ||
| + | [[2vnt]], [[2r2w]] - hUK + guanidine derivative<br /> | ||
| + | [[1w0z]], [[1w10]], [[1w11]], [[1w12]], [[1w13]], [[1w14]] - hUK + alanineamide derivative<br /> | ||
| + | |||
| + | ===Urokinase C terminal complex with inhibitors=== | ||
| - | [[4fu7]], [[4fu8]], [[4fu9]], [[4fub]] - hUK B chain catalytic domain + inhibitor<br /> | ||
| - | [[1fv9]] – hUK B chain (mutant) + benzimidazole derivative – human<br /> | ||
| - | [[1f5k]] - hUK B chain (mutant) + benzamidine derivative<br /> | ||
| - | [[1f5l]] - hUK B chain (mutant) + amiloride derivative<br /> | ||
| - | [[1f92]], [[1sc8]], [[1vj9]], [[1vja]], [[2o8t]], [[2o8u]], [[2o8w]] - hUK B chain (mutant) + inhibitor<br /> | ||
| - | [[1owd]], [[1owe]], [[1owh]], [[1owi]], [[1owj]], [[1owk]], [[1sqa]], [[1sqo]], [[1u6q]], [[1sqt]], [[4fuc]], [[4fud]], [[4fue]], [[4fuf]], [[4fug]], [[4fuh]], [[4fui]], [[4fuj]]- hUK B chain + naphthamidine inhibitor<br /> | ||
| - | [[1ejn]] - hUK B chain (mutant) + urea derivative inhibitor<br /> | ||
[[3kgp]] – hUK Hc C terminal (mutant) + benzoic acid derivative<br /> | [[3kgp]] – hUK Hc C terminal (mutant) + benzoic acid derivative<br /> | ||
[[3khv]] - hUK Hc C terminal (mutant) + methanol derivative<br /> | [[3khv]] - hUK Hc C terminal (mutant) + methanol derivative<br /> | ||
| Line 27: | Line 34: | ||
[[3ox7]], [[3oy5]], [[3oy6]] - hUK Hc C terminal (mutant) + peptide inhibitor<br /> | [[3ox7]], [[3oy5]], [[3oy6]] - hUK Hc C terminal (mutant) + peptide inhibitor<br /> | ||
[[3kid]], [[3mhw]] - hUK Hc C terminal (mutant) + aminobenzothiazole derivative<br /> | [[3kid]], [[3mhw]] - hUK Hc C terminal (mutant) + aminobenzothiazole derivative<br /> | ||
| - | [[2vin]], [[2vio]], [[2vip]], [[2viq]], [[2viv]], [[2viw]] - hUK B chain catalytic domain (mutant) + mexiletine derivative<br /> | ||
| - | [[3qn7]] - hUK B chain catalytic domain (mutant) + peptide inhibitor<br /> | ||
| - | [[2vnt]], [[2r2w]] - hUK B chain catalytic domain + guanidine derivative<br /> | ||
| - | [[1w0z]], [[1w10]], [[1w11]], [[1w12]], [[1w13]], [[1w14]] - hUK B chain catalytic domain + alanineamide derivative<br /> | ||
[[2nwn]], [[4gly]] - hUK Hc C terminal + cyclic peptide<br /> | [[2nwn]], [[4gly]] - hUK Hc C terminal + cyclic peptide<br /> | ||
[[3m61]] - hUK Hc C terminal (mutant) + cyclic peptide | [[3m61]] - hUK Hc C terminal (mutant) + cyclic peptide | ||
| - | ===Urokinase | + | ===Urokinase short chain + catalytic domain complex with inhibitors=== |
[[1lmw]] – hUK A+B catalytic domain + EGRCMK<br /> | [[1lmw]] – hUK A+B catalytic domain + EGRCMK<br /> | ||
Revision as of 10:21, 30 December 2013
Urokinase (UK) is a serine protease whose principal substrate is plasminogen – the inactive zymogen of plasmin. UK consists of 3 domains: ligand-binding domain and kringle and growth factor domains. Prourokinase (PUK) is the inactive zymogen of UK which becomes active by proteolytic cleavage into catalytic domain (residues 179-431) and short chain (residues 156-178).
Contents |
3D Structures of urokinase
Updated on 30-December-2013
2i9a - hUK Hc N terminal (residues 21-163) - human
1kdu – hUK kringle domain (residues 69-153) - NMR
4dva – hUK catalytic domain (residues 179-431)
Urokinase catalytic domain complex with inhibitors
4fu7, 4fu8, 4fu9, 4fub - hUK + inhibitor
1fv9 – hUK (mutant) + benzimidazole derivative – human
1f5k - hUK (mutant) + benzamidine derivative
1f5l - hUK (mutant) + amiloride derivative
1f92, 1sc8, 1vj9, 1vja, 2o8t, 2o8u, 2o8w, 4h42 - hUK (mutant) + inhibitor
1owd, 1owe, 1owh, 1owi, 1owj, 1owk, 1sqa, 1sqo, 1u6q, 1sqt, 4fuc, 4fud, 4fue, 4fuf, 4fug, 4fuh, 4fui, 4fuj- hUK + naphthamidine inhibitor
1ejn - hUK (mutant) + urea derivative inhibitor
2vin, 2vio, 2vip, 2viq, 2viv, 2viw - hUK (mutant) + mexiletine derivative
3qn7, 4jk5, 4jk6 - hUK (mutant) + peptide inhibitor
2vnt, 2r2w - hUK + guanidine derivative
1w0z, 1w10, 1w11, 1w12, 1w13, 1w14 - hUK + alanineamide derivative
Urokinase C terminal complex with inhibitors
3kgp – hUK Hc C terminal (mutant) + benzoic acid derivative
3khv - hUK Hc C terminal (mutant) + methanol derivative
3mwi - hUK Hc C terminal (mutant) + amidine derivative
3ox7, 3oy5, 3oy6 - hUK Hc C terminal (mutant) + peptide inhibitor
3kid, 3mhw - hUK Hc C terminal (mutant) + aminobenzothiazole derivative
2nwn, 4gly - hUK Hc C terminal + cyclic peptide
3m61 - hUK Hc C terminal (mutant) + cyclic peptide
Urokinase short chain + catalytic domain complex with inhibitors
1lmw – hUK A+B catalytic domain + EGRCMK
1c5w, 1c5x, 1c5y, 1c5z - hUK A+B chain catalytic domain + carboxamidine derivative
1gi7, 1gi8, 1gi9, 1gj7, 1gj8, 1gj9, 1gja, 1gjb, 1gjc, 1gjd - hUK A+B chain catalytic domain (mutant) + carboxamidine derivative
1o3p, 1o5a, 1o5b, 1o5c - hUK A+B chain catalytic domain (mutant) + benzenolate derivative
3ig6 – hUK A+B chain catalytic domain + inhibitor
Urokinase complex with protein
2fd6 – hUK Hc N terminal + antibody + UK receptor
3bt1, 3bt2 - hUK Hc N terminal + vitronectin + UK receptor
3laq, 3u73 - hUK Hc N terminal + UK receptor
3pb1 - hUK Hc C terminal (mutant) + UK inhibitor
2i9b - hUK Hc N terminal + UK receptor (mutant)
4dw2 - hUK B chain catalytic domain + antibody
